Signify Premium Insight: Riding out the Storm: Amwell and Teladoc Financials Q4/FY2022
Published: March 2, 2023
In the face of sustained macro-economic challenges, Amwell and Teladoc continue to wage battle on several fronts. As in previous quarters, Teladoc is riding out the post-Covid storm better than its rival on several counts. But, amid the pervading global gloom, the telehealth industry is in decent overall shape; and there are some genuine bright spots in both companies’ Q4 and full-year (FY) 2022 financial results. This offers grounds for guarded optimism in 2023 and beyond.
Amwell at a Loss
By far Amwell’s most pressing challenge is how to stem losses which have been a black mark on the company’s bottom line since the end of the Covid telehealth boom. In 2022, soaring inflation intensified the problem, pushing operating expenses ever higher.
Read the full insight with a Signify Premium Insights – Digital Health subscriptionSign up for a free trial today.
Telehealth – Market Intelligence ServiceOngoing series of reports, data and insights delivered over the year
Telehealth – Market Intelligence Service
This Market Intelligence Service provides rolling 12-month coverage of the global telehealth market in both acute and ambulatory applications.
Find out more